Mutations in the HTT gene, which cause Huntington’s disease, lead to abnormalities in development as early as two weeks after conception, a new study indicates. The study, “Huntingtin CAG expansion impairs germ layer patterning in synthetic human 2D gastruloids through polarity defects,” was published in Development.
News
Horizon Therapeutics has launched its #RAREis Representation program aimed at increasing diversity, equity, and inclusion among patients with rare diseases. There are about 400 million people worldwide living with a rare disease; for many of them, access to diagnosis, care, and treatments can be challenging. Accessing better care depends on…
Sage Therapeutics is recruiting participants for a clinical trial to test the effects of its experimental therapy SAGE-718 on cognitive symptoms in people with Huntington’s disease. The Phase 2 study, called DIMENSION (NCT05107128), is seeking participants in select regions of the U.S. with additional sites in the…
Bionews, the publisher of this website, hosted a virtual panel discussion on Rare Disease Day 2022, taking a deeper dive into what it’s like to live with a rare disease, including conversations about advocacy, mental health, survivor’s guilt, treatment of minority patients, and more. The Monday event, “A…
The Huntington’s Disease Society of America (HDSA) will contribute nearly $1.9 million to its Centers of Excellence program this year, growing it by one site plus two regional partner sites. These additions bring to 55 the number of grant-funded Centers of Excellence located across the U.S. and to 10…
A rare disease puts an economic burden on the patients, families, and caregivers that it affects, and will no doubt be an integral part of discussions on Rare Disease Day 2022, which brings international awareness about the more than 300 million people living with rare disorders. Part of that…
The nonprofit RARE-X is creating an easily-accessible, centralized data hub for all rare disease patient data that can help researchers answer questions about existing disorders, discover new ones, and work toward finding treatments. It was spun out of the work that Nicole Boice, founder and chief engagement officer of…
Spending more time on leisure activities — which contributes to a person’s cognitive reserve, or the ability to improvise — is associated with lesser cognitive and functional decline in people with early manifest Huntington’s disease, a study shows. In addition, a greater number of CAG repeats within the HTT gene…
It’s been nearly a year since the EveryLife Foundation for Rare Diseases released its expansive report finding the total economic burden of rare disorders in the U.S. to be nearly $1 trillion.
The first two patients in Europe have been dosed in uniQure’s Phase 1/2 clinical trial investigating AMT-130, a one-time investigational gene therapy for Huntington’s disease. The trial is underway in Poland, where it is still open for enrollment, and is expected to expand to other sites in the…
Recent Posts
- Huntington’s treatment safely slows disease over 9 months in early trial
- A new puppy gives my gene-positive wife a sense of purpose
- Toward a better understanding of anger as a symptom of Huntington’s disease
- Actor Will Forte shares family story in Teva awareness campaign
- Finding ‘space in the middle’ to deal with life’s challenges
- What a compassionate reset looks like in life with Huntington’s
- Ingrezza engages with therapeutic target more strongly than Austedo
- Anticipation of a possible new clinical trial has us holding on to hope
- What caregiver burnout is really about — and what you can do about it
- Oral Huntington’s treatment aims to slow disease progression